Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sweat gland carcinoma with neuroendocrine differentiation of the scalp with elevated serum chromogranin A levels.

JAAD case reports·2025

Same author

Primary Malignant Melanoma of the Lung (PMML); A Case Report.

Cureus·2023

Same author

Intravenous Iron Replacement for Iron Deficiency Anemia [FPIN's Clinical Inquiries].

American family physician·2023

Same author

Primary anaplastic large cell lymphomas of the pancreas.

Proceedings (Baylor University. Medical Center)·2022

Same author

An unusual myeloid sarcoma.

Proceedings (Baylor University. Medical Center)·2022

Same author

Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma.

Case reports in hematology·2021

Same journal

Evaluating the rising incidence of infant botulism and the heterogeneous distribution of cases in Texas in the wake of the November 2025 outbreak.

Proceedings (Baylor University. Medical Center)·2026

Same journal

Young-onset signet ring cell colorectal adenocarcinoma: demographics, clinicopathological profile, and survival analysis.

Proceedings (Baylor University. Medical Center)·2026

Same journal

Supporting patient understanding of cervical and ovarian cancer: how well does AI perform?

Proceedings (Baylor University. Medical Center)·2026

Same journal

Nationwide analysis of adult nongonococcal septic knee arthritis hospitalizations from 2016 to 2022.

Proceedings (Baylor University. Medical Center)·2026

Same journal

Ferrier and Horsley in America, 1888: cerebral localization and neurosurgery.

Proceedings (Baylor University. Medical Center)·2026

Same journal

Anesthetic management of a high-risk cesarean delivery in a patient with multivessel Takayasu arteritis.

Proceedings (Baylor University. Medical Center)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

T-cell prolymphocytic leukemia.

Robbie L Graham¹, Barry Cooper, John R Krause

¹Department of Pathology, Section of Hematopathology (Graham, Krause), and the Department of Hematology/Oncology (Cooper), Baylor University Medical Center at Dallas and the Baylor Charles A. Sammons Cancer Center at Dallas.

Proceedings (Baylor University. Medical Center)

|February 6, 2013

Summary

This summary is machine-generated.

T-cell prolymphocytic leukemia (T-PLL) is an aggressive cancer. This case report details a de novo T-PLL diagnosis, highlighting its unique features and poor prognosis.

More Related Videos

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Area of Science:

Hematology
Oncology
Leukemia Research

Background:

T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy.
It is characterized by the proliferation of prolymphocytes of postthymic origin.
T-PLL typically presents with aggressive clinical behavior and poor response to chemotherapy.

Purpose of the Study:

To report a case of de novo T-cell prolymphocytic leukemia.
To discuss the distinctive clinical, morphologic, immunophenotypic, and cytogenetic features of T-PLL.
To emphasize the aggressive nature and limited treatment options for T-PLL.

Main Methods:

Case report of a de novo T-cell prolymphocytic leukemia.
Review of clinical presentation.
Analysis of morphologic, immunophenotypic, and cytogenetic findings.

Main Results:

The patient presented with de novo T-cell prolymphocytic leukemia.
Distinctive clinical, morphologic, immunophenotypic, and cytogenetic features were observed.
The disease course was aggressive, consistent with known T-PLL characteristics.

Conclusions:

T-cell prolymphocytic leukemia is an aggressive malignancy with unique features.
Hematopoietic stem cell transplantation remains the only potential curative option.
Further research into novel therapeutic strategies is warranted.